Synthesis and anticoagulant bioactivity evaluation of 1,2,5-trisubstituted benzimidazole fluorinated derivatives

Abstract

Some 1,2,5-trisubstituted benzimidazole fluorinated derivatives were designed and screened by molecular docking. Five compounds which obtained high scores were selected to synthesize. All the target products were cha-racterized by ¹H NMR, ¹³C NMR and high resolution mass spectra(HRMS) and preliminarily screened for inhibitory activity against thrombin, among which three compounds(5a, 5c and 5e) were evaluated in vitro. The results showed that compounds 5a, 5c and 5e exhibited better anticoagulant activity than argatroban. Docking simulations demon-strated that these compounds may act as candidates for further studies on thrombin inhibitors.

Keywords

Benzimidazole derivative / Fluorine / Anticoagulant bioactivity / Molecular docking

References

[1] Dobesh P. P., Fanikos J. Drugs, 2014, 74(17): 1.

[2] Cohen A. T., Giancarlo A., Anderson F. A., Arcelus J. I., Bergqvist D., Brecht J. G., Greer I. A., Heit J. A., Hutchinson J. L., Kakkar A. K., Mottier D., Oger E., Samama M. M., Spannagl M. Thromb. Haemostasis, 2007, 98(4): 756.

[3] Perez A., Eraso L. H., Merli G. J. Int. J. Clin. Pract., 2013, 67(2): 139.

[4] Coughlin M. A., Bartlett R. H. Asaio J., 2015, 61(6): 652.

[5] Robertson L., Kesteven P. Cochrane Db. Syst. Rev., 2015, 12(1): 1.

[6] Finazzi G., Ageno W. Intern. Emerg. Med., 2016, 11(2): 167.

[7] Schwienhorst A. Cell. Mol. Life Sci., 2006, 63(23): 2773.

[8] William B., Hillegass M. M. Catheter. Cardio. Inte., 2016, 87(3): 401.

[9] Lee C. J., Ansell J. E. Brit. J. Clin. Pharmaco., 2011, 72(4): 581.

[10] Alban S. Curr. Pharm. Design, 2008, 14(12): 1152.

[11] Kathiresan S., Jin S., Jang I. K. J. Thromb. Thrombolys., 2002, 13(1): 41.

[12] Elmasry A. H., Fahmy H. H., Abdelwahed S. H. A. Molecules, 2014, 5(12): 1429.

[13] Masashi M., César P. B., Pavel A. Org. Lett., 2011, 13(18): 4882.

[14] Sawant R., Kawade D. Acta Pharmaceut., 2011, 61(3): 353.

[15] Nile S. H., Brajesh K., Park S. W. Chem. Biol. Drug Des., 2013, 82(3): 290.

[16] Gupta R. P., Larroquette C. A., Agrawal K. C. J. Med. Chem., 1982, 25(11): 1342.

[17] Hauel N. H., Nar H., Priepke H., Ries U., Stassen J. M., Wienen W. J. Med. Chem., 2002, 45(9): 1757.

[18] Hyohdoh I., Furuichi N., Aoki T., Itezono Y., Shirai H., Ozawa S., Watanabe F., Matsushita M., Sakaitani M., Ho P. S., Takanashi K., Harada N., Tomii Y., Yoshinari K., Ori K., Tabo M., Aoki Y., Shimma N., Iikura H. ACS Med. Chem. Lett., 2013, 4(11): 1059.

[19] Jiang W., María S. R., JoséL A., Carlos D. P., Alexander E. S., Santos F., Soloshonok V. A., Liu H. Chem. Rev., 2014, 114(4): 2432.

[20] Gillis E. P., Eastman K. J., Hill M. D., Donnelly D. J., Meanwell N. A. J. Med. Chem., 2015, 58(21): 8315.

[21] Rowley M., Hallett D. J., Goodacre S., Moyes C., Crawforth J., Sparey T. J., Patel S., Marwood R., Patel S., Thomas S., Hitzel L., Connor C. O., Szeto N., Castro J. L., Hutson P. H., Macleod A. M. J. Med. Chem., 2001, 44(10): 1603.

[22] Kirk K. L. J. Fluorine Chem., 2006, 127(8): 1013.

[23] Mohamed N. A., El-Serwy W. S., El-Karim S. S. A., Awad G. E., Elseginy S. A. Res. Chem. Intermediat., 2016, 42(2): 1363.

[24] Nayak P. S., Narayana B., Sarojini B. K., Fernades J., Bharath B. R., Madhu L. N. Med. Chem. Res., 2015, 24(12): 4191.

[25] Li C. L., Dong M. H., Ren Y. J., Li L. H. RSC Adv., 2015, 5(30): 23737.

[26] Pilli R. A., Rodrigues M. T. J. Braz. Chem. Soc., 2009, 20(8): 1434.

[27] Ren W. X., Ren Y. J., Dong M. H., Gao Y. H. Helv. Chim. Acta, 2016, 4(99): 325.